XML 46 R31.htm IDEA: XBRL DOCUMENT v3.25.4
General and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Inventory, Current [Table Text Block]
Inventories consist of the following (in thousands):
As of December 31,
 20252024
Raw materials$265,383 $265,275 
Work in process38,097 37,528 
Finished goods312,379 281,873 
Total$615,859 $584,676 
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment consists of the following (in thousands): 
As of December 31,
 20252024
Machinery and equipment$434,959 $400,861 
Land, building and building improvements176,972 177,089 
Molds107,296 96,318 
Computer equipment and software116,259 122,208 
Furniture and fixtures23,055 27,871 
Instruments placed with customers(1)
148,441 124,290 
Construction in progress90,748 87,006 
Total property, plant and equipment, cost1,097,730 1,035,643 
Accumulated depreciation(645,913)(592,897)
Property, plant and equipment, net
$451,817 $442,746 
_______________________________
(1)     Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives.  Estimated useful lives are:
Buildings
15 - 30 years
Building improvements
15 - 30 years
Machinery and equipment and molds
2 - 15 years
Furniture, fixtures and office equipment
2 - 5 years
Computer equipment and software
3 - 5 years
Instruments placed with customers
3 - 10 years
Schedule of Goodwill
The following table presents the changes in the carrying amount of our goodwill for 2025, 2024 and 2023 (in thousands):
Total
Balance as of January 1, 2023$1,449,258 
Currency translation23,188 
Balance as of December 31, 2023
1,472,446 
Currency translation(39,674)
Balance as of December 31, 2024
1,432,772 
Currency translation66,982 
Balance as of December 31, 2025
$1,499,754 
Schedule of Indefinite-Lived Intangible Assets
Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):
 Weighted-Average Amortization Life
in Years		December 31, 2025
 CostAccumulated
Amortization		Net
Patents10$40,582 $25,455 $15,127 
Customer contracts129,959 7,356 2,603 
Non-contractual customer relationships8561,199 304,287 256,912 
Trademarks15,425 5,425 — 
Trade name1518,249 9,574 8,675 
Developed technology(1)
10637,589 293,506 344,083 
Non-compete39,100 9,100 — 
    Total amortized intangible assets $1,282,103 $654,703 $627,400 
Internally developed software(2)
$6,159 $6,159 
Total intangible assets$1,288,262 $654,703 $633,559 
_______________________________
(1)    Developed technology primarily consists of acquired patented technologies and internally developed software. Upon completion of development, the assets are amortized over their estimated useful lives.
(2)    Internally developed software will be reclassified to developed technology and amortized when the projects are complete and the assets are ready for their intended use. During 2025, we reclassified $11.4 million to developed technology.

 Weighted-Average Amortization Life
in Years		December 31, 2024
 CostAccumulated
Amortization		Net
Patents10$36,811 $22,913 $13,898 
Customer contracts129,818 6,994 2,824 
Non-contractual customer relationships8546,404 236,267 310,137 
Trademarks15,425 5,425 — 
Trade name1518,239 8,357 9,882 
Developed technology(1)
10619,540 227,869 391,671 
Non-compete39,100 9,100 — 
Total amortized intangible assets $1,245,337 $516,925 $728,412 
Internally developed software(2)
$12,377 $12,377 
Total intangible assets$1,257,714 $516,925 $740,789 
_______________________________
(1)    Developed technology primarily consists of acquired patented technologies and internally developed software. Upon completion of development, the assets are amortized over their estimated useful lives.
(2)    Internally developed software will be reclassified to developed technology and amortized when the projects are complete and the assets are ready for their intended use. During 2024, we reclassified $33.2 million to developed technology.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
As of December 31, 2025, estimated annual amortization for our intangible assets for each of the next five years and thereafter is approximately (in thousands):
2026$136,384 
2027120,367 
2028119,768 
2029116,676 
203054,191 
Thereafter80,014 
Total$627,400 
Equity Method Investments
Our investment in unconsolidated affiliates consist of the following (in thousands):

As of December 31,
20252024
Otsuka ICU Medical LLC$128,662 $— 
Other equity method investment2,924 3,038 
$131,586 $3,038 
Interest Income and Interest Expense Disclosure
Interest expense, net
The following table presents interest expense, net (in thousands): 
As of December 31,
202520242023
Interest expense$(93,338)$(106,541)$(102,727)
Interest income10,307 10,788 7,508 
Interest expense, net$(83,031)$(95,753)$(95,219)
Schedule of Other Nonoperating Income (Expense)
Other expense, net

The following table presents other expense, net (in thousands): 
As of December 31,
202520242023
Foreign exchange gains (losses), net$3,786 $(9,792)$(5,918)
Loss on disposition of assets(4,366)(1,608)(153)
Other miscellaneous income (expense) , net348 (1,823)166 
Other expense, net$(232)$(13,223)$(5,905)
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data): 
 Year ended December 31,
 202520242023
Net income (loss)$732 $(117,688)$(29,655)
Weighted-average number of common shares outstanding (basic)24,640 24,388 24,091 
Dilutive securities264 — — 
Weighted-average common and common equivalent shares outstanding (diluted)24,904 24,388 24,091 
EPS — basic$0.03 $(4.83)$(1.23)
EPS — diluted$0.03 $(4.83)$(1.23)
Total anti-dilutive stock options and restricted stock awards (shares in thousands)
40 42 129